SELECTED FINANCIAL STATEMENT INFORMATION (Tables)

9 Months Ended

Jul. 31, 2016

Selected Financial Statement Information [Abstract]

Schedule of Accounts Receivable [Table Text Block]

Accounts Receivable

(in thousands)	July 31, 2016			October 31, 2015
Accounts receivable		$192,875			$183,631
Less: Allowance for doubtful accounts	(3,258		)	(2,038		)
Accounts receivable, net		$189,617			$181,593

Schedule of Costs in Excess of Billings and Billings in Excess of Costs [Table Text Block]

Costs and Estimated Earnings on Uncompleted Percentage-of-Completion Contracts

(in thousands)	July 31, 2016			October 31, 2015
Costs incurred on uncompleted contracts		$31,831			$22,645
Estimated earnings	25,608			16,116
	57,439			38,761
Less: Billings to date	(48,652		)	(36,442		)
		$8,787			$2,319
Included in the accompanying Condensed Consolidated Balance Sheets under the following captions:
Accounts receivable, net (costs and estimated earnings in excess of billings)		$10,628			$6,263
Accrued expenses and other current liabilities (billings in excess of costs and estimated earnings)	(1,841		)	(3,944		)
		$8,787			$2,319

Schedule of Inventories [Table Text Block]

Inventories

(in thousands)	July 31, 2016			October 31, 2015
Finished products		$130,523			$119,262
Work in process	36,333			32,201
Materials, parts, assemblies and supplies	116,910			89,739
Contracts in process	4,111			4,521
Less: Billings to date	(1,198		)	(2,206		)
Inventories, net of valuation reserves		$286,679			$243,517

Schedule of Property, Plant and Equipment [Table Text Block]

Property, Plant and Equipment

(in thousands)	July 31, 2016			October 31, 2015
Land		$5,092			$5,060
Buildings and improvements	75,732			70,626
Machinery, equipment and tooling	168,735			152,022
Construction in progress	10,189			4,668
	259,748			232,376
Less: Accumulated depreciation and amortization	(140,813		)	(126,706		)
Property, plant and equipment, net		$118,935			$105,670

Schedule of Research and Development Expenses [Table Text Block]

The amount of new product research and development ("R&D") expenses included in cost of sales for the nine and three months ended July 31, 2016 and 2015 is as follows (in thousands):

	Nine months ended July 31,				Three months ended July 31,
	2016		2015		2016		2015
R&D expenses		$32,666		$28,860		$12,674		$9,421

Schedule of Redeemable Noncontrolling Interests [Table Text Block]

Management's estimate of the aggregate Redemption Amount of all Put Rights that the Company could be required to pay is as follows (in thousands):

	July 31, 2016		October 31, 2015
Redeemable at fair value		$73,553		$76,929
Redeemable based on a multiple of future earnings	14,353		14,353
Redeemable noncontrolling interests		$87,906		$91,282

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

Changes in the components of accumulated other comprehensive loss for the nine months ended July 31, 2016 are as follows (in thousands):

	Foreign Currency Translation			Pension Benefit Obligation			Accumulated Other Comprehensive Loss
Balances as of October 31, 2015		($24,368	)		($712	)		($25,080	)
Unrealized gain	2,708			—			2,708
Balances as of July 31, 2016		($21,660	)		($712	)		($22,372	)